Geoffrey is the President and CEO of Kaleido. He is also a Partner at Flagship VentureLabs®, where he focuses on inventing technologies and starting companies to address global challenges in medicine, nutrition, and environmental sustainability. He is a co-founder of Seres Therapeutics, Pronutria Biosciences, Indigo, and others. Geoffrey served as Chief Technology Officer at Seres Therapeutics, where he led the build-out of the Microbiome Therapeutics platform and the discovery of SER-109, the first clinically-validated Microbiome Therapeutic, and VP Product Discovery at Pronutria, where he led discovery of two clinically-validated drug candidates. Geoffrey has been named as an inventor on over 100 patents and applications and received more than 20 awards for invention, including the Lemelson-MIT student prize, given to the most innovative student at MIT. He was awarded a Ph.D. in Biomedical Engineering and Medical Physics from MIT; a M.S. in Bioengineering from the University of California, San Diego; and a S.B. in Chemical Engineering from MIT.
Ruth Thieroff-Ekerdt is the Chief Medical Officer at Kaleido. She was formerly the CMO at Strongbridge, and prior to that, Aptalis. Dr. Thieroff-Ekerdt has over 25 years of international experience in the pharmaceutical industry. Prior to joining Aptalis, she served as Eurand’s Chief Medical Officer since December 2008. Earlier in her career, she held the position of Vice President of Clinical and Medical Affairs at Bayer Consumer Care. In addition, she held various positions with Berlex, Inc. and Schering AG, including Vice President of Medical Development Management and Operations, Vice President of Clinical Development, and Director of Clinical Development, Dermatology, and Head of the Laboratory of Vitamin D Research. Dr. Thieroff-Ekerdt graduated from medical school at the Free University of Berlin. Dr. Thieroff-Ekerdt holds a medical degree and specialized in Pharmacology/Toxicology.
Dr. Silverman’s career has focused on the discovery and development of novel antibiotics to treat serious, drug resistant infections in the hospital setting. He is currently VP of Research at Kaleido, following 18 years at Cubist Pharmaceuticals where he contributed to the discovery of three novel antibiotics that entered clinical development, including as the biology lead for the discovery of Surotomycin, currently in Phase 3 trials for the treatment of C. difficile. Additionally, Dr Silverman and his collaborators pursued studies into the mechanism of action of the lipopeptide antibiotic daptomycin and the mechanisms of resistance to this clinically important antibiotic. He undertook postdoctoral training at Yale University and has a PhD in Microbiology from Harvard Medical School. Dr. Silverman serves as a member of the UK MRC’s Antimicrobial Resistance steering group.
Jack Milwid is VP of Strategy for Kaleido, and Senior Associate at Flagship VentureLabs®. Jack is a serial entrepreneur, and before joining Kaleido, he led the internal effort at Third Rock Ventures to create and launch the cancer immunotherapy company Neon Therapeutics. Prior to Third Rock, Jack co-founded three companies while a graduate student in the lab of Martin Yarmush at the Massachusetts General Hospital, and a post-doctoral fellow in the labs of Biju Parekkadan at MGH, and Michael Cima at MIT. He has helped raise over $60M in grant and venture financing. Jack has a Ph.D. in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology, an M.S. in materials science and engineering from MIT, and a B.S. in metallurgical and materials engineering from the Colorado School of Mines.